Baiyunshan Subsidiary Secures New Drug Registration for Heart Medication

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (stock code: 600332) announced that its branch, Baiyunshan Pharmaceutical General Factory, has received a drug registration certificate from the National Medical Products Administration for Trimetazidine Dihydrochloride Sustained-Release Tablets (35mg). This chemical drug, classified as a Class 4, has a registration number 2025S02152 and is valid until July 14, 2030.

The drug, used for stable angina, was first approved in China on June 4, 2010. Baiyunshan Pharmaceutical General Factory submitted its application on January 4, 2024, and received approval on January 12, 2024. The company has invested RMB 9,189,300 in research and development for this product. This approval is expected to strengthen the company's competitiveness in the cardiovascular medication market.